NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

GRFS

Grifols SA ADR

Jul 03 • 01:30PM ET

9.08

Dollar change -0.06
Percentage change -0.66	%

Healthcare • Drug Manufacturers - General • Spain • NASD

Peers: JNJ BMY PFE MRK LLY AMGN GILD BAX ABT CANF

| Held by: IBB BINV SPDW BSMC KOMP APIE CGIC ONEQ IBBQ BIB

Scroll to Statements

Index	-	P/E	29.52	EPS (ttm)	0.31	Insider Own	0.06%	Shs Outstand	258.22M	Perf Week	3.42%
Market Cap	2.34B	Forward P/E	7.97	EPS next Y	1.14	Insider Trans	0.00%	Shs Float	258.07M	Perf Month	8.87%
Enterprise Value	15.25B	PEG	1.20	EPS next Q	-	Inst Own	57.97%	Short Float	1.07%	Perf Quarter	21.23%
Income	209.19M	P/S	0.30	EPS this Y	19.44%	Inst Trans	-8.90%	Short Ratio	3.49	Perf Half Y	22.70%
Sales	7.91B	P/B	1.01	EPS next Y	30.66%	ROA	0.90%	Short Interest	2.76M	Perf YTD	22.04%
Book/sh	8.95	P/C	2.88	EPS next 5Y	24.53%	ROE	3.34%	52W High	9.96 -8.84%	Perf Year	44.59%
Cash/sh	3.15	P/FCF	2.26	EPS past 3/5Y	-8.79% -24.56%	ROIC	1.29%	52W Low	6.19 46.69%	Perf 3Y	-26.18%
Dividend Est.	0.03 (0.31%)	EV/EBITDA	8.50	Sales past 3/5Y	10.19% 6.45%	Gross Margin	38.10%	Volatility	2.14% 2.33%	Perf 5Y	-51.52%
Dividend TTM	-	EV/Sales	1.93	EPS Y/Y TTM	1.92%	Oper. Margin	16.66%	ATR (14)	0.24	Perf 10Y	-42.46%
Dividend Ex-Date	Jun 03, 2021	Quick Ratio	0.97	Sales Y/Y TTM	9.67%	Profit Margin	2.64%	RSI (14)	62.51	Recom	3.33
Dividend Gr. 3/5Y	- -	Current Ratio	2.60	EPS Q/Q	170.18%	SMA20	2.63%	Beta	0.55	Target Price	9.85
Payout	0.00%	Debt/Eq	1.78	Sales Q/Q	6.52%	SMA50	11.31%	Rel Volume	0.24	Prev Close	9.14
Employees	23833	LT Debt/Eq	1.67	Earnings	May 12 AMC	SMA200	13.76%	Avg Volume	791.82K	Price	9.08
IPO	Jun 02, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.24% -6.10%	Trades		Volume	191,164	Change	-0.66%

Date	Action	Analyst	Rating Change
Feb-12-25	Resumed	Morgan Stanley	Overweight
Mar-12-24	Downgrade	Deutsche Bank	Hold → Sell
Apr-12-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-03-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-16-23	Upgrade	Barclays	Underweight → Equal Weight
Jan-18-23	Upgrade	Jefferies	Hold → Buy
Apr-08-22	Initiated	Morgan Stanley	Equal-Weight
Nov-05-21	Downgrade	Deutsche Bank	Buy → Hold
Oct-19-21	Downgrade	Barclays	Overweight → Underweight
Oct-06-21	Upgrade	Citigroup	Neutral → Buy
Jun-14-21	Upgrade	Deutsche Bank	Hold → Buy
Apr-20-21	Initiated	Deutsche Bank	Hold
Mar-23-21	Upgrade	Credit Suisse	Neutral → Outperform
Mar-11-21	Upgrade	HSBC Securities	Hold → Buy
Oct-01-20	Upgrade	Citigroup	Sell → Neutral
Jun-09-20	Upgrade	HSBC Securities	Reduce → Hold
Jun-09-20	Downgrade	Citigroup	Neutral → Sell
Mar-25-20	Downgrade	Citigroup	Buy → Neutral
Jun-27-19	Upgrade	JP Morgan	Neutral → Overweight
Feb-08-19	Downgrade	Berenberg	Buy → Hold

Show Previous Ratings

Jun-27-25 08:11AM	Will Strong Asceniv Sales Drive ADMA Biologics Further? (Zacks)
Jun-16-25 01:06PM	ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? (Zacks)
Jun-06-25 10:40AM	ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? (Zacks)
Jun-05-25 12:00PM	Grifols (GRFS) Is Up 2.47% in One Week: What You Should Know (Zacks)
Jun-03-25 09:40AM	Is Grifols (GRFS) Stock Undervalued Right Now? (Zacks)
11:40AM	Loading…
Jun-02-25 11:40AM	GRFS vs. STVN: Which Stock Is the Better Value Option? (Zacks)
May-30-25 04:05PM	Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting (Business Wire)
May-28-25 10:01AM	ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? (Zacks)
May-22-25 05:34AM	FDA clears Grifols application for dry eye disease treatment (Clinical Trials Arena)
May-15-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
May-13-25 11:48AM	Grifols reports Q1 adjusted EBITDA of EUR 400M, up 14.2% from last year (TipRanks)
11:46AM	Grifols reaffirms guidance for 2025 (TipRanks)
May-08-25 01:26PM	ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? (Zacks)
May-01-25 01:22PM	Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings? (Zacks)
Apr-30-25 06:17AM	Australia's CSL evaluates China tariff exemptions for its US-made drugs (Reuters)
08:40AM	Loading…
Apr-28-25 08:40AM	Here's White Falcon's Views on Grifols, S.A. (GRFS) (Insider Monkey)
Apr-23-25 11:10AM	Grifols: A Market Setback Turns Into Buying Opportunity (Seeking Alpha)
10:50AM	White Falcon Capital Q1 2025 Partner's Letter (Seeking Alpha)
Apr-09-25 06:32AM	IBL partners with Grifols to develop biomarker panels for speciality diagnostics (Medical Device Network) +6.78%
Apr-02-25 07:27AM	Stocks to Watch Wednesday: Tesla, Nvidia, Newsmax, Novo Nordisk (The Wall Street Journal) +7.61%
03:03AM	Spanish pharma company Grifols' shares up on Brookfield talk (Reuters)
Feb-27-25 09:16AM	Is Grifols, S.A. (GRFS) the Best Low Price Pharma Stock to Invest In Right Now? (Insider Monkey)
06:00AM	Grifols SA (GIFLF) (Q4 2024) Earnings Call Highlights: Record Revenues and Strategic ... (GuruFocus.com)
Jan-22-25 10:22AM	Gotham, Grifols Eye Two Separate Regulator Reports Ahead of Legal Standoff (Bloomberg)
Jan-14-25 06:00AM	Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease (GlobeNewswire)
Jan-13-25 10:55AM	Mason Capital complains about Grifols' transparency to Spanish regulator (Reuters)
10:00AM	Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols (Business Wire)
Dec-13-24 05:24AM	Grifols Worst-Ever Year Cant Derail Analyst Calls to Buy (Bloomberg)
04:14AM	Grifols Keeps Door Open to Brookfield With Special Bond Term (Bloomberg)
Dec-10-24 01:07PM	Flat Footed Asks Grifols to Reform Board to Protect Shareholders (Bloomberg)
10:34AM	Loading…
Dec-06-24 10:34AM	Analyst Report: Grifols, S.A. (Morningstar Research)
Dec-05-24 03:40AM	SEC Drops Probe Into Gotham Over Report on Grifols Accounts (Bloomberg)
Dec-04-24 02:30AM	Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga (Business Wire)
Dec-03-24 05:13AM	Grifols Shareholder Mason Capital Calls for Board Overhaul (Bloomberg)
Nov-29-24 09:29AM	Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday? (Benzinga) -13.38%
Nov-28-24 07:39AM	Billionaire Grifols Family Woes in Focus as Brookfield Exits (Bloomberg)
07:09AM	Grifols In Talks to Refinance Debt, Credit Line, CEO Says (Bloomberg)
Nov-27-24 09:02AM	Brookfield Drops $6.8 Billion Offer to Buy Drugmaker Grifols (Bloomberg) -7.45%
06:58AM	Brookfield Set to Drop Grifols Bid as Family Shuns Others (Bloomberg)
Nov-20-24 07:30AM	GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment (Clinical Trials Arena)
02:16AM	Grifols Signals It Would Reject $6.8 Billion Brookfield Bid (Bloomberg)
Nov-19-24 11:16PM	Analyst Report: Grifols, S.A. (Morningstar Research) -8.24%
08:00AM	GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus (GlobeNewswire)
07:33AM	Brookfield Weighs 6.45 Billion Bid for Grifols; Shares Drop (Bloomberg)
02:30AM	Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors (Business Wire)
Nov-14-24 11:37AM	Banks to Pitch Roughly 11 Billion Buyout Debt for Grifols (Bloomberg) +5.06%
Nov-08-24 06:01PM	Grifols SA (GIFLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Cash ... (GuruFocus.com)
03:54PM	Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors (Business Wire)
10:27AM	Analyst Report: Grifols, S.A. (Morningstar Research)
Nov-05-24 12:02PM	Brookfield Seeks More Information on Grifols Related-Party Deals (Bloomberg) +5.57%
Oct-30-24 08:28AM	Grifols receives FDA approval to treat surgical bleeding with FS solution (TipRanks) +6.95%
Oct-29-24 08:00AM	Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution (GlobeNewswire)
Oct-22-24 08:00AM	Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury (GlobeNewswire)
Oct-03-24 08:00AM	GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat (GlobeNewswire)
Sep-19-24 04:00PM	Grifols Investor Group With 7.7% Holding Seeks Seat on Board (Bloomberg)
Sep-10-24 01:37PM	Grifols Holders Call on Family, Brookfield to Offer Fair Price (Bloomberg)
Sep-03-24 05:41AM	Grifols Postpones Capital Markets Day Amid Potential Takeover (Bloomberg)
Aug-29-24 12:22PM	Brookfield Courts Sovereign Funds to Join Grifols Takeover Bid (Bloomberg)
Aug-26-24 07:00AM	This Reviled Pharmaceutical Firm Holds Promise of a Healthier Future (The Wall Street Journal)
Aug-22-24 11:01AM	Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday (Zacks) +15.38%
Aug-21-24 12:19PM	Brookfield in talks with banks for funding Grifols' takeover bid, sources say (Reuters) +6.68%
05:33AM	Brookfield Seeks Nearly 10 Billion to Back Grifols Takeover (Bloomberg)
05:14AM	Grifols shares up on potential takeover by Brookfield (Investing.com)
Aug-07-24 07:02PM	Azvalor Iberia FI's Strategic Moves in Q2 2024: Spotlight on Linea Directa Aseguradora SA (GuruFocus.com)
Aug-02-24 01:21PM	Grifols S.A. (GRFS) Admits Improper Accounting, Announces Restatements, Shares Decline Again - Hagens Berman (Business Wire)
Jul-31-24 12:27PM	Grifols: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339 (GlobeNewswire)
Jul-30-24 07:42PM	Analyst Report: Grifols, S.A. (Morningstar Research)
11:35AM	Grifols Cuts Chinese Stake Value by 457 Million After Audit (Bloomberg)
Jul-29-24 08:00AM	Grifols receives expanded XEMBIFY (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients (GlobeNewswire)
Jul-09-24 11:28AM	Grifols Family Shareholders, Brookfield in Talks To Take Firm Private (Investopedia)
Jul-08-24 01:00PM	3 Stocks to Buy From the Ultimate' Buy-and-Hold Portfolio (InvestorPlace) +19.46%
12:36PM	GRFS Stock Alert: Grifols Pops 20% on Takeover Interest (InvestorPlace)
11:36AM	Analyst Report: Grifols, S.A. (Morningstar Research)
11:16AM	Beleaguered Spanish Drug Firm Grifols Stock Jumps On Monday - Here's Why (Benzinga)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:18AM	Grifols Says Founding Family, Brookfield Weigh Takeover Bid (Bloomberg)
Jul-01-24 06:00AM	Grifols' Biotest to achieve USD 1 billion in US sales of Yimmugo over next seven years (GlobeNewswire)
Jun-18-24 07:30AM	Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group (GlobeNewswire)
Jun-17-24 11:54AM	Biotest wins FDA approval for plasma protein therapy (Pharmaceutical Technology)
10:13AM	Grifols prepares for late-stage plans with plasma-derived medicines in 2024 (Pharmaceutical Technology)
04:20AM	Grifols' Biotest receives FDA approval for innovative Yimmugo immunoglobulin to treat primary immunodeficiencies (GlobeNewswire)
Jun-07-24 03:32PM	Analyst Report: Grifols, S.A. (Morningstar Research)
May-21-24 04:31AM	GigaGen doses first subject in Phase I advanced solid tumour trial (Clinical Trials Arena)
May-20-24 08:07AM	Grifols, S.A. (NASDAQ:GRFS) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:00AM	GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors (GlobeNewswire)
May-14-24 06:02PM	Analyst Report: Grifols, S.A. (Morningstar Research)
May-09-24 10:07AM	Short Seller Gains on Grifols Bet That Tripped Elliott Spinout (Bloomberg)
May-06-24 12:18PM	Grifols Shares Rise as Haier Deal Set to Close in June (MT Newswires) +6.85%
Apr-19-24 04:42PM	Grifols 2023 Annual Report on Form 20-F filed with the SEC (PR Newswire)
Apr-18-24 09:30AM	Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. (GlobeNewswire)
Apr-14-24 07:16AM	Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper (Reuters)
Apr-10-24 04:01AM	Grifols Plans First Bond Sale Since Short Seller Attack (Bloomberg)
Apr-04-24 04:00AM	Grifols Procleix ArboPlex Assay Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening (GlobeNewswire)
Mar-29-24 02:11PM	Grifols S.A. (GRFS ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report Hagens Berman (GlobeNewswire)
Mar-25-24 01:25PM	Grifols S.A. (GRFS ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report Hagens Berman (GlobeNewswire)
Mar-22-24 08:03AM	Grifols Drops as Regulator Finds Relevant Deficiencies (Bloomberg) -8.26%
Mar-20-24 01:21PM	Grifols S.A. (GRFS ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report Hagens Berman (GlobeNewswire)
Mar-08-24 06:25PM	Analyst Report: Grifols, S.A. (Morningstar Research) +24.78%
12:34PM	Health Care Roundup: Market Talk (The Wall Street Journal)

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by Jose Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GRFS

Grifols SA ADR

Upgrade your FINVIZ experience